The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study.
Adolescent
Adult
Black or African American
Anti-HIV Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
Baltimore
/ epidemiology
COVID-19
/ epidemiology
Condoms
/ statistics & numerical data
HIV Infections
/ epidemiology
Health Services Accessibility
/ statistics & numerical data
Homosexuality, Male
Humans
Incidence
Male
Models, Statistical
Pre-Exposure Prophylaxis
/ statistics & numerical data
Prognosis
Risk-Taking
Sexual Partners
Survival Analysis
White People
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
30
10
2020
revised:
18
01
2021
accepted:
22
01
2021
pubmed:
23
2
2021
medline:
16
4
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
During the COVID-19 pandemic, men who have sex with men (MSM) in the USA have reported similar or fewer sexual partners and reduced HIV testing and care access compared with before the pandemic. Pre-exposure prophylaxis (PrEP) use has also declined. We aimed to quantify the potential effect of COVID-19 on HIV incidence and HIV-related mortality among US MSM. We used a calibrated, deterministic, compartmental HIV transmission model for MSM in Baltimore (MD, USA) and available data on COVID-19-related disruptions to HIV services to predict effects of reductions in sexual partners (0%, 25%, 50%), condom use (5%), HIV testing (20%), viral suppression (10%), PrEP initiations (72%), PrEP adherence (9%), and antiretroviral therapy (ART) initiations (50%). In our main analysis, we modelled disruptions due to COVID-19 starting Jan 1, 2020, and lasting 6 months. We estimated the median change in cumulative new HIV infections and HIV-related deaths among MSM over 1 and 5 years, compared with a base case scenario without COVID-19-related disruptions. A 25% reduction in sexual partners for 6 months among MSM in Baltimore, without HIV service changes, could reduce new HIV infections by median 12·2% (95% credible interval 11·7 to 12·8) over 1 year and median 3·0% (2·6 to 3·4) over 5 years. In the absence of changes in sexual behaviour, the 6-month estimated reductions in condom use, HIV testing, viral suppression, PrEP initiations, PrEP adherence, and ART initiations combined are predicted to increase new HIV infections by median 10·5% (5·8 to 16·5) over 1 year, and by median 3·5% (2·1 to 5·4) over 5 years. Disruptions to ART initiations and viral suppression are estimated to substantially increase HIV-related deaths (ART initiations by median 1·7% [0·8 to 3·2], viral suppression by median 9·5% [5·2 to 15·9]) over 1 year, with smaller proportional increases over 5 years. The other individual disruptions (to HIV testing, PrEP and condom use, PrEP initiation, and partner numbers) were estimated to have little effect on HIV-related deaths (<1% change over 1 or 5 years). A 25% reduction in sexual partnerships is estimated to offset the effect of the combined service disruptions on new HIV infections (change over 1 year: median -3·9% [-7·4 to 1·0]; over 5 years: median 0·0% [-0·9 to 1·4]), but not on HIV deaths (change over 1 year: 11·0% [6·2 to 17·7]; over 5 years: 2·6% [1·5 to 4·3]). Maintaining access to ART and adherence support is of the utmost importance to maintain viral suppression and minimise excess HIV-related mortality due to COVID-19 restrictions in the USA, even if disruptions to services are accompanied by reductions in sexual partnerships. National Institutes of Health.
Sections du résumé
BACKGROUND
During the COVID-19 pandemic, men who have sex with men (MSM) in the USA have reported similar or fewer sexual partners and reduced HIV testing and care access compared with before the pandemic. Pre-exposure prophylaxis (PrEP) use has also declined. We aimed to quantify the potential effect of COVID-19 on HIV incidence and HIV-related mortality among US MSM.
METHODS
We used a calibrated, deterministic, compartmental HIV transmission model for MSM in Baltimore (MD, USA) and available data on COVID-19-related disruptions to HIV services to predict effects of reductions in sexual partners (0%, 25%, 50%), condom use (5%), HIV testing (20%), viral suppression (10%), PrEP initiations (72%), PrEP adherence (9%), and antiretroviral therapy (ART) initiations (50%). In our main analysis, we modelled disruptions due to COVID-19 starting Jan 1, 2020, and lasting 6 months. We estimated the median change in cumulative new HIV infections and HIV-related deaths among MSM over 1 and 5 years, compared with a base case scenario without COVID-19-related disruptions.
FINDINGS
A 25% reduction in sexual partners for 6 months among MSM in Baltimore, without HIV service changes, could reduce new HIV infections by median 12·2% (95% credible interval 11·7 to 12·8) over 1 year and median 3·0% (2·6 to 3·4) over 5 years. In the absence of changes in sexual behaviour, the 6-month estimated reductions in condom use, HIV testing, viral suppression, PrEP initiations, PrEP adherence, and ART initiations combined are predicted to increase new HIV infections by median 10·5% (5·8 to 16·5) over 1 year, and by median 3·5% (2·1 to 5·4) over 5 years. Disruptions to ART initiations and viral suppression are estimated to substantially increase HIV-related deaths (ART initiations by median 1·7% [0·8 to 3·2], viral suppression by median 9·5% [5·2 to 15·9]) over 1 year, with smaller proportional increases over 5 years. The other individual disruptions (to HIV testing, PrEP and condom use, PrEP initiation, and partner numbers) were estimated to have little effect on HIV-related deaths (<1% change over 1 or 5 years). A 25% reduction in sexual partnerships is estimated to offset the effect of the combined service disruptions on new HIV infections (change over 1 year: median -3·9% [-7·4 to 1·0]; over 5 years: median 0·0% [-0·9 to 1·4]), but not on HIV deaths (change over 1 year: 11·0% [6·2 to 17·7]; over 5 years: 2·6% [1·5 to 4·3]).
INTERPRETATION
Maintaining access to ART and adherence support is of the utmost importance to maintain viral suppression and minimise excess HIV-related mortality due to COVID-19 restrictions in the USA, even if disruptions to services are accompanied by reductions in sexual partnerships.
FUNDING
National Institutes of Health.
Identifiants
pubmed: 33617783
pii: S2352-3018(21)00022-9
doi: 10.1016/S2352-3018(21)00022-9
pmc: PMC8045548
mid: NIHMS1684590
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e206-e215Subventions
Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069412
Pays : United States
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
AIDS Behav. 2021 Jan;25(1):40-48
pubmed: 32876905
J Acquir Immune Defic Syndr. 2021 May 1;87(1):639-643
pubmed: 33512848
Sex Transm Dis. 2020 Jul;47(7):434-436
pubmed: 32520878
AIDS Behav. 2020 Jul;24(7):2013-2016
pubmed: 32300993
Lancet Glob Health. 2020 Sep;8(9):e1102-e1103
pubmed: 32673576
J Int AIDS Soc. 2019 Mar;22(3):e25246
pubmed: 30868739
Lancet HIV. 2020 May;7(5):e308-e309
pubmed: 32272084
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
Lancet HIV. 2020 Jun;7(6):e384-e385
pubmed: 32359421
J Infect Dis. 2021 Mar 29;223(6):1019-1028
pubmed: 33507308
J Acquir Immune Defic Syndr. 2021 May 1;87(1):644-651
pubmed: 33443963
MMWR Morb Mortal Wkly Rep. 2020 May 22;69(20):630-631
pubmed: 32437340
MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603
pubmed: 31298662
Sex Res Social Policy. 2021 Aug 20;:1-15
pubmed: 34457080
AIDS Behav. 2021 Feb;25(2):311-321
pubmed: 32654021
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
Clin Infect Dis. 2021 Oct 5;73(7):e1964-e1972
pubmed: 32905581
Drug Alcohol Depend. 2020 Nov 1;216:108260
pubmed: 32890975
AIDS Behav. 2020 Jul;24(7):2024-2032
pubmed: 32350773
AIDS. 2020 Dec 1;34(15):2328-2331
pubmed: 32910069
Open Forum Infect Dis. 2020 Jul 02;7(7):ofaa275
pubmed: 32704518
AIDS Behav. 2020 Oct;24(10):2770-2772
pubmed: 32382823
Clin Infect Dis. 2021 Jun 1;72(11):e828-e834
pubmed: 33045723
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089